Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
312
resultados
Última actualización
13/09/2026 [07:20:00]
Resultados 125 a 150 de 312
Resumen de: US20260232812A1
0000 The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
Resumen de: WO2025058005A1
Provided is a biomarker for use in the determination or diagnosis of a progression rate of amyotrophic lateral sclerosis (ALS) or a possibility of being affected by ALS and/or the selection or prediction of a therapeutic drug for ALS. There is discovered a biomarker selected from the group consisting of IL-17A, KLRD1, KRT19, NCF2, TFF2, YTHDF3, Th17, a regulatory T cell (Treg), mature CD8T, naive CD8T, exhausted CD8T, a Classical monocyte, memory CD4T, Th17/Treg, mature CD8T/naive CD8T, and mature CD8T/exhausted CD8T.
Resumen de: WO2021236836A2
Methods of detecting a condition comprising neoangiogenesis, ischemia, or both, or risk thereof in a subject. Methods of inhibiting, ameliorating, delaying the onset of, reducing the likelihood of, treating, or preventing a condition comprising perfusion shortage (such as neoangiogenesis, ischemia, or both) in a subject in need thereof are described. Kits are described.
Resumen de: WO2021202793A2
Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion/activation processes utilizing IL-2, IL-7, IL-15, and/or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.
Resumen de: EP4790418A1
0001 The present invention refers to the diagnosis, prognosis, monitoring and/or treatment of comorbidities in people living with human immunodeficiency virus (HIV) (PLWH).
Resumen de: WO2018094116A1
Methods are provided of identifying a subject having impaired aldehyde dehydrogenase activity; and administering to the subject a compound comprising an isotopicaliy-modified polyunsaturated fatty acid, an isotopicaliy-modified polyunsaturated fatty acid ester, an isotopicaliy-modified polyunsaturated fatty acid thioester, an isotopicaliy-modified polyunsaturated fatty acid amide, a polyunsaturated fatty acid mimetic, or an isotopicaliy-modified polyunsaturated fatty acid pro-drug, the compound having an isotopic modification that reduces oxidation of the compound, thereby reducing production in the subject of substrate for aldehyde dehydrogenase. Some aspects provide coadministering an isotopicaliy-modified polyunsaturated fatty acid and an oxylipin.
Resumen de: AU2012262122A1
The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Resumen de: WO2021247009A1
A method of treating a cancer in a mammalian subject with a tumor signature characterized by any one or more of (i) a level of sirtuin (SIRT3) protein that is below a first predetermined threshold level, (ii) a level of manganese superoxide dismutase acetylated at the lysine 68 residue (AcK68) that exceeds a second predetermined threshold level, and (iii) expression levels of hypoxia-inducible factor 2α (HIF2α) that exceed a third predetermined threshold level indicative of lineage plasticity for stemness, the method comprising administering to the mammalian subject a therapeutically effective amount of a pentaaza macrocyclic ring complex corresponding to the Formula (I) below, optionally with administration of a further anti-cancer therapeutic agent.
Resumen de: WO2024215624A2
This disclosure provides antibodies and methods for preparing and using the same wherein the antibodies bind to PTGFRN on a cell.
Resumen de: CN122541562A
本申请涉及一种特异性识别磷酸化Tau217蛋白的单克隆抗体、其制备方法，以及包含该抗体的磷酸化Tau217蛋白检测试剂盒，该抗体可用于阿尔茨海默病的早期辅助诊断、病程监测及疗效评估。本发明试剂盒空白限为0.51 pg/mL，检出限为1.04 pg/mL，定量限为3.93 pg/mL，线性范围0.5‑100 pg/mL（线性相关系数r≥0.99），批内精密度CV≤8%，批间精密度CV≤15%，抗干扰性良好，试剂盒稳定性为12个月，开瓶后机载稳定期30天，与进口参比试剂盒相关性良好。
Resumen de: EP4790416A2
The present invention relates to a method comprising the step detecting in a sample an antibody binding specifically to NECAB1, an antibody binding specifically to NECAB1, a carrier such as a diagnostically useful carrier with a solid phase with an immobilized polypeptide comprising an antigen or at least one epitope thereof or a variant of the antigen or epitope thereof, wherein the antigen is NECAB1, and a use of the antibody for diagnosing an autoimmune disease or a cancer.
Resumen de: WO2025026908A1
The present invention relates to methods of diagnosing whether a subject has endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, and methods of monitoring endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain progression in a subject, by determining the amount or concentration of EphA1 in a sample of the subject, and comparing the determined level to a reference value.
Resumen de: WO2025249975A1
The present invention relates to a novel compound for detecting amyloid-beta and a method for diagnosing degenerative brain disease using same, the compound represented by chemical formula 1 or a salt thereof, according to the present invention, being capable of specifically binding to amyloid-beta. The compound or a salt thereof has high selectivity and thus may detect amyloid-beta in plasma with high sensitivity despite interference in the detection due to the presence of other proteins in plasma, and may be utilized for diagnosing degenerative brain disease or screening a therapeutic agent for degenerative brain disease.
Resumen de: WO2025017127A1
Gp130 antigen-binding antibodies are disclosed which inhibit IL-6, IL-11, OSM, LIF, CNTF, CT-1 mediated signal and bind to the cytokine binding region. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, humanised antibodies and therapeutic methods using, the Gp130 antigen-binding antibodies.
Resumen de: CN122520771A
0001 本发明公开了一种抗β‑淀粉样前体蛋白的抗体及其相关产品和应用，所述抗体可特异性结合β‑淀粉样前体蛋白，具有高亲和力和特异性，所述相关产品包括包含所述抗体的检测试剂盒、检测试剂，可用于β‑淀粉样前体蛋白的检测或β‑淀粉样前体蛋白相关疾病（如：阿尔茨海默病、轻度认知障碍、淀粉样变性相关神经退行性疾病）的诊断或辅助诊断，为临床诊疗提供可靠的分子检测依据。
Resumen de: CN122525140A
0001 本发明涉及生物标志物组合在制备用于APOE ε3/ε3基因型个体阿尔茨海默病的检测试剂盒中的应用，所述的生物标志物选自ANGPTL1，PON2，PTN，SCGB3A1，PBLD，MORC3，EIF5A，FAM3D，PIKFYVE，CKB，HGF，TREH，GSTA3，EIF2AK3，CTSD，FOLH1中的至少一种，实现了在该人群中对阿尔茨海默病高精度、高特异性的体外诊断。
Resumen de: CN122525131A
本发明属于检测技术领域，本发明具体公开了一种磷酸化Tau217蛋白测定试剂盒及应用，本申请所述的磷酸化Tau217蛋白测定试剂盒包括特定的抗试剂A、抗试剂B和磁微粒试剂，所述的生物素标记的p‑Tau 217抗体与碱性磷酸酶标记的p‑Tau 217抗体反应生成，抗体‑抗原‑抗体复合物并通过生物素与链霉亲和素的特异性结合反应结合到磁性微粒上，能够有效的降低检测限，实现了磷酸化Tau217蛋白的高灵敏度检测，空白限不高于0.20pg/mL，且在0.50pg/mL~50.00pg/mL范围内线性相关性好（r≥0.9900），可实现磷酸化Tau217蛋白的准确定量。
Resumen de: WO2024192404A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: CN122525111A
0001 本发明公开了一种血浆TRAIL水平检测在阿尔茨海默病检测中的应用，涉及生物医学检测技术领域；一种检测人血浆中肿瘤坏死因子相关凋亡诱导配体浓度的物质在制备用于辅助评估受试者阿尔茨海默病相关认知状态的试剂中的应用；所述应用包括：将受试者的血浆TRAIL浓度检测值与预设的参考值范围或诊断阈值进行比较，其中，当所述血浆TRAIL浓度高于用于区分AD与认知功能正常状态的第一诊断阈值时，为辅助判断所述受试者更可能处于AD状态而非CU状态提供信息。本发明基于血浆样本进行检测，仅需常规静脉采血，避免了腰椎穿刺的侵入性风险和PET成像的放射性暴露及高额费用。所使用的酶联免疫吸附测定等技术成熟、操作相对标准化。
Resumen de: CN122525107A
0001 本发明涉及生物标志物技术领域，尤其涉及C1酯酶抑制剂的岩藻糖含量检测试剂在制备2型遗传性血管水肿诊断产品中的应用。本发明发现C1酯酶抑制剂的岩藻糖基化水平与2型遗传性血管水肿具有显著相关性，可用于诊断2型遗传性血管水肿；经ROC曲线验证，C1酯酶抑制剂的岩藻糖基化水平对于2型遗传性血管水肿具有较好的诊断性能，且具有检测方便、所需时间短等优势，可单独或与其他标志物组合用于2型遗传性血管水肿诊断，在2型遗传性血管水肿诊断中具有较好的应用前景。
Resumen de: US20260227416A1
0000 The invention relates to diagnosis, prevention, and treatment of diseases and conditions associated with the functions of prion-like or Tetz-proteins.
Resumen de: US20260226658A1
0000 Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.
Resumen de: US20260226172A1
The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
Resumen de: US20260227412A1
The present invention provides for the use of IFN-I activity as a predictive biomarker for the treatment of patients with toll-like receptor (TLR) inhibitors and related uses and methods.
Nº publicación: US20260229316A1 06/08/2026
Solicitante:
GAUDILLIERE BRICE [US]
HEDOU JULIEN [FR]
VERDONK FRANCK [FR]
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV [US]
ASSIST PUBLIQUE HOPITAUX DE PARIS [FR]
INST PASTEUR [FR]
Gaudilli\u00E8re Brice
H\u00E9dou Julien
Verdonk Franck
The Board of Trustees of the Leland Stanford Junior University
Assistance Publique-H\u00F4pitaux de Paris
Institut Pasteur
Resumen de: US20260229316A1
Embodiments herein describe systems and methods to generate a risk score for an individual to develop postoperative neurocognitive disorder (POND). Various embodiments obtain multi-omics data from an individual, such as genomics, transcriptomics, and proteomics. In certain embodiments, a machine learning algorithm is used to generate the risk score based on the multi-omics data. In further embodiments, clinical data is further used in the determination of the risk score.
BOPI
Sede Electrónica
